S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
URGENT: Sell these stocks by September 13th (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
URGENT: Sell these stocks by September 13th (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
URGENT: Sell these stocks by September 13th (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
URGENT: Sell these stocks by September 13th (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
URGENT: Sell these stocks by September 13th (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
URGENT: Sell these stocks by September 13th (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
URGENT: Sell these stocks by September 13th (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
URGENT: Sell these stocks by September 13th (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Positive News Sentiment  
NASDAQ:KZR

Kezar Life Sciences - KZR Stock Forecast, Price & News

$9.76
-0.28 (-2.79%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.64
▼
$10.36
50-Day Range
$4.58
▼
$10.49
52-Week Range
$4.30
▼
$18.55
Volume
847,666 shs
Average Volume
1.38 million shs
Market Capitalization
$589.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.67

Kezar Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
101.5% Upside
$19.67 Price Target
Short Interest
Healthy
9.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
1.88mentions of Kezar Life Sciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.13) to ($1.25) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

368th out of 1,112 stocks

Pharmaceutical Preparations Industry

184th out of 544 stocks

See Top Rated MarketRank™ Stocks Here
KZR stock logo

About Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Kezar Life Sciences Price Performance

Shares of KZR Stock opened at $10.04 on Thursday. Kezar Life Sciences has a 12-month low of $4.30 and a 12-month high of $18.55. The business has a 50 day simple moving average of $8.15 and a 200 day simple moving average of $11.02. The company has a debt-to-equity ratio of 0.04, a current ratio of 35.25 and a quick ratio of 35.25.

Kezar Life Sciences (NASDAQ:KZR - Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.03. Sell-side analysts anticipate that Kezar Life Sciences will post -1.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on KZR shares. Jonestrading increased their price objective on Kezar Life Sciences from $17.00 to $20.00 in a report on Tuesday, June 28th. Wells Fargo & Company increased their price objective on Kezar Life Sciences from $13.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday, June 28th.

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Stock News Headlines

August 11, 2022 | finance.yahoo.com
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
July 27, 2022 | seekingalpha.com
Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case
July 18, 2022 | finance.yahoo.com
Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?
July 11, 2022 | finance.yahoo.com
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
July 8, 2022 | finance.yahoo.com
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating
July 7, 2022 | finance.yahoo.com
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
June 28, 2022 | finance.yahoo.com
Wells Fargo Beefs Up Kezar Life Price Target - Read Why
June 28, 2022 | finance.yahoo.com
Why Kezar Life Sciences Stock Is Crushing It Today
June 28, 2022 | seekingalpha.com
Kezar rises 92% after mid-stage data for lead asset in lupus nephritis
June 27, 2022 | markets.businessinsider.com
After-Hours Action: Why Kezar Life Sciences Stock Is Soaring
June 27, 2022 | finance.yahoo.com
Early lupus patient data sends Kezar Life Sciences' stock soaring after-hours
June 27, 2022 | markets.businessinsider.com
Kezar Life Sciences Stock Surges 105% On Positive Data Drug Trial Results
June 27, 2022 | seekingalpha.com
Kezar climbs ~83% after mid-stage data for lupus nephritis candidate
June 27, 2022 | markets.businessinsider.com
Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate
June 27, 2022 | finance.yahoo.com
Billionaire Israel Englander Pulls the Trigger on These 2 “Strong Buy” Stocks
June 27, 2022 | finance.yahoo.com
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
June 10, 2022 | finance.yahoo.com
Down 10.7% in 4 Weeks, Here's Why Kezar Life Sciences, Inc. (KZR) Looks Ripe for a Turnaround
June 6, 2022 | morningstar.com
Kezar Life Sciences Inc - Stock News
May 23, 2022 | finance.yahoo.com
After Plunging 59.3% in 4 Weeks, Here's Why the Trend Might Reverse for Kezar Life Sciences, Inc. (KZR)
May 23, 2022 | finance.yahoo.com
Kezar Life Sciences, Inc. (KZR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
May 13, 2022 | finance.yahoo.com
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 | finance.yahoo.com
Health Check: How Prudently Does Kezar Life Sciences (NASDAQ:KZR) Use Debt?
May 5, 2022 | finance.yahoo.com
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 4, 2022 | finance.yahoo.com
Wells Fargo Analyst Has Questions On Kezar's Lupus Nephritis Data Readout, Stock Plunges
May 4, 2022 | marketwatch.com
Kezar Life Sciences Shares Slide Premarket on Zetomipzomib Study >KZR
See More Headlines
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Company Calendar

Last Earnings
11/09/2021
Today
8/11/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZR
CUSIP
N/A
CIK
1645666
Web
www.kezarlifesciences.com
Phone
(650) 822-5600
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.67
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+101.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-54,630,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-33.99%
Return on Assets
-31.15%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
35.25
Quick Ratio
35.25

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.01 per share
Price / Book
2.43

Miscellaneous

Outstanding Shares
60,416,000
Free Float
55,764,000
Market Cap
$589.66 million
Optionable
Not Optionable
Beta
0.16

Key Executives

  • Mr. John Franklin Fowler (Age 49)
    Co-Founder, CEO & Director
    Comp: $905.06k
  • Dr. Christopher J. Kirk Ph.D. (Age 49)
    Co-Founder, Pres, Chief Scientific Officer & Director
    Comp: $658.81k
  • Dr. Noreen Roth Henig M.D. (Age 57)
    Chief Medical Officer
    Comp: $705.53k
  • Dr. Jack Taunton Ph.D.
    Co-Founder
  • Mr. Marc L. Belsky (Age 67)
    CFO & Sec.
  • Mr. Michael Wolfe
    VP of Fin. & Bus. Operations
  • Ms. Gitanjali Jain
    VP of Investor Relations & External Affairs
  • Mr. Mark Schiller
    Sr. VP of Legal Affairs
  • Dr. Neel K. Anand Ph.D.
    VP of Medicinal Chemistry & Head of Drug Discovery
  • Ms. Pattie Chiang
    VP & Corp. Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KZR Stock - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KZR shares.
View KZR analyst ratings or view top-rated stocks.

What is Kezar Life Sciences' stock price forecast for 2022?

2 brokers have issued twelve-month price objectives for Kezar Life Sciences' stock. Their KZR share price forecasts range from $17.00 to $22.00. On average, they anticipate the company's share price to reach $19.67 in the next twelve months. This suggests a possible upside of 102.1% from the stock's current price.
View analysts price targets for KZR or view top-rated stocks among Wall Street analysts.

How have KZR shares performed in 2022?

Kezar Life Sciences' stock was trading at $16.72 at the beginning of 2022. Since then, KZR shares have decreased by 41.8% and is now trading at $9.73.
View the best growth stocks for 2022 here.

When is Kezar Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our KZR earnings forecast.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02.

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (4.59%), Deutsche Bank AG (0.50%), Connor Clark & Lunn Investment Management Ltd. (0.40%), Russell Investments Group Ltd. (0.19%), Simplex Trading LLC (0.00%) and Swiss National Bank (0.17%). Insiders that own company stock include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Michael Kauffman, Middleton Angus, Morningside Venture Investment and Vassiliki Economides.
View institutional ownership trends.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $9.73.

How much money does Kezar Life Sciences make?

Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $587.89 million. The company earns $-54,630,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.

This page (NASDAQ:KZR) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.